FDA declines to move forward with schizophrenia treatment

The FDA has issued a Complete Response Letter for the New Drug Application for risperidone extended-release injectable for subcutaneous use, a schizophrenia treatment, Teva Pharmaceuticals and MedinCell announced in a statement.
The FDA states on its website that it will send a Complete Response Letter if the agency determines it will not approve the application in its present form.
According to Teva and MedinCell, the NDA submitted included data from two phase 3 trials, which evaluated the safety, efficacy and tolerability of the treatment.
Both companies stated that they are committed to the

The FDA has issued a Complete Response Letter for the New Drug Application for risperidone extended-release injectable for subcutaneous use, a schizophrenia treatment, Teva Pharmaceuticals and MedinCell announced in a statement.
The FDA states on its website that it will send a Complete Response Letter if the agency determines it will not approve the application in its present form.
According to Teva and MedinCell, the NDA submitted included data from two phase 3 trials, which evaluated the safety, efficacy and tolerability of the treatment.
Both companies stated that they are committed to the